CR9958A - Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco - Google Patents

Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco

Info

Publication number
CR9958A
CR9958A CR9958A CR9958A CR9958A CR 9958 A CR9958 A CR 9958A CR 9958 A CR9958 A CR 9958A CR 9958 A CR9958 A CR 9958A CR 9958 A CR9958 A CR 9958A
Authority
CR
Costa Rica
Prior art keywords
farmaco
reconstitution
dilution
solution
injection
Prior art date
Application number
CR9958A
Other languages
English (en)
Inventor
Chandra A Webb
Julie Zerfas
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37801586&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9958(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9958A publication Critical patent/CR9958A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion proporciona metodos para la preparacion de formulaciones farmaceuticas para inyeccion tal que en la inyeccion la formualcion no provoque la aglutinacion de eritrocitos, hemolisis, y/o contraccion de celulas. Para prevenir la aglutinacion, una formulacion farmaceutica preparada para inyeccion necesita tener una fuerza ionica suficiente. Para prevenir la hemolisis o la contraccion de celulas, una formulacion farmaceutica preparada para inyeccion necesita ser casi isotonica con respecto al plasma.
CR9958A 2005-11-01 2008-05-07 Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco CR9958A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73222105P 2005-11-01 2005-11-01

Publications (1)

Publication Number Publication Date
CR9958A true CR9958A (es) 2008-07-29

Family

ID=37801586

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9958A CR9958A (es) 2005-11-01 2008-05-07 Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco

Country Status (31)

Country Link
US (4) US20070135343A1 (es)
EP (3) EP3225233B1 (es)
JP (1) JP5555425B2 (es)
KR (2) KR20110128957A (es)
CN (1) CN101351190B (es)
AR (2) AR056748A1 (es)
AU (1) AU2006308921C1 (es)
BR (1) BRPI0618133A2 (es)
CA (1) CA2626531C (es)
CR (1) CR9958A (es)
DK (2) DK3225233T3 (es)
EC (1) ECSP088485A (es)
ES (2) ES2749574T3 (es)
FI (1) FI1942868T4 (es)
FR (1) FR20C1005I1 (es)
GT (1) GT200800037A (es)
HK (1) HK1245090B (es)
HU (4) HUE045421T2 (es)
IL (1) IL190843A (es)
LU (1) LUC00035I2 (es)
MY (1) MY184364A (es)
NO (1) NO347263B1 (es)
NZ (1) NZ567685A (es)
PE (3) PE20070714A1 (es)
PL (2) PL1942868T5 (es)
PT (2) PT1942868T (es)
RU (1) RU2432157C2 (es)
SI (2) SI1942868T2 (es)
TW (1) TWI480063B (es)
UA (1) UA97234C2 (es)
WO (1) WO2007053533A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA97234C2 (ru) 2005-11-01 2012-01-25 Уайєт Раствор хлорида натрия для восстановления влагосодержания композиции лиофилизированного фактора ix
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US8431011B2 (en) * 2008-01-31 2013-04-30 Abbott Diabetes Care Inc. Method for automatically and rapidly distinguishing between control and sample solutions in a biosensor strip
KR101614983B1 (ko) * 2009-11-17 2016-04-22 입센 파마 에스.에이.에스 Ｈｇｈ 및 ｒｈｉｇｆ―１의 조합물을 위한 제제
US10634741B2 (en) 2009-12-04 2020-04-28 Endomagnetics Ltd. Magnetic probe apparatus
US9427186B2 (en) 2009-12-04 2016-08-30 Endomagnetics Ltd. Magnetic probe apparatus
EA031209B9 (ru) 2010-01-15 2021-11-19 Кирин-Эмджен, Инк. Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
BR112012022223B1 (pt) * 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
SG10201913700SA (en) 2010-07-09 2020-03-30 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
HK1213521A1 (zh) * 2012-09-25 2016-07-08 Bioverativ Therapeutics Inc. Fix多肽的應用
CN105283202B (zh) 2013-03-11 2019-04-23 安都磁学有限公司 用于淋巴结检测的低渗溶液
US9234877B2 (en) 2013-03-13 2016-01-12 Endomagnetics Ltd. Magnetic detector
US9239314B2 (en) 2013-03-13 2016-01-19 Endomagnetics Ltd. Magnetic detector
EA037906B1 (ru) * 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
EP3123090A4 (en) * 2014-03-24 2017-12-13 Bioverativ Therapeutics Inc. Lyophilized factor ix formulations
US9351945B1 (en) * 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
GB2536703B (en) * 2015-03-27 2020-12-02 Ge Healthcare Bio Sciences Ab Method for baseline correction in a chromatogram
EP3081942A1 (en) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample
EP3782575A1 (en) 2015-06-04 2021-02-24 Endomagnetics Ltd. Marker materials and forms for magnetic marker localization (mml)
US10124021B2 (en) * 2016-12-23 2018-11-13 Andrew L. Gostine Intravenous fluid
JP7110360B2 (ja) 2017-10-09 2022-08-01 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥方法
JP7541993B2 (ja) 2019-03-14 2024-08-29 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥用ローディングトレイ組立体、凍結乾燥システム及び凍結乾燥方法
US12036187B2 (en) * 2019-05-01 2024-07-16 Southwest Research Institute Compositions of dimethyl trisulfide (DMTS) as a cyanide antidote
US20220387416A1 (en) * 2019-10-25 2022-12-08 Cmc Pharmaceuticals, Inc. Atropine-scopolamine with enhanced stability
IL272145A (en) 2020-01-20 2021-07-29 Stem Cell Medicine Ltd Cosmetic compositions with protein concentrate from conditioned medium of adipose-derived stem cells
US12274450B2 (en) * 2020-08-03 2025-04-15 Transluminal Systems, Llc Devices and methods for trans-arterial osmotic embolization of pathological tissue

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717708A (en) * 1968-10-24 1973-02-20 Cutter Lab Blood coagulation complex
US4364861A (en) 1980-05-27 1982-12-21 Cutter Laboratories, Inc. Blood-coagulation-promoting products and methods of preparing them
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
PT2193809E (pt) 1999-02-22 2015-08-24 Baxter Int Formulações de fator viii livres de albumina
US20010031721A1 (en) * 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
PT1324776E (pt) * 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
ES2676644T3 (es) * 2003-12-19 2018-07-23 Novo Nordisk Health Care Ag Composiciones estabilizadas de polipéptidos de factor VII
EP1720519A1 (en) * 2004-03-04 2006-11-15 Wyeth Lyophilization method to improve excipient crystallization
UA97234C2 (ru) 2005-11-01 2012-01-25 Уайєт Раствор хлорида натрия для восстановления влагосодержания композиции лиофилизированного фактора ix

Also Published As

Publication number Publication date
WO2007053533A3 (en) 2007-12-06
US20200338199A1 (en) 2020-10-29
PL3225233T3 (pl) 2019-12-31
CN101351190B (zh) 2013-01-02
DK1942868T4 (da) 2023-11-06
HUE033949T2 (hu) 2018-01-29
WO2007053533A2 (en) 2007-05-10
ES2749574T3 (es) 2020-03-23
SI1942868T1 (sl) 2017-07-31
NO20082180A (no) 2008-07-04
ES2627684T5 (es) 2024-04-29
KR101126670B1 (ko) 2012-04-23
PL1942868T3 (pl) 2017-09-29
EP1942868B1 (en) 2017-04-19
PT3225233T (pt) 2019-10-24
US20070135343A1 (en) 2007-06-14
CA2626531C (en) 2011-11-29
TW200803915A (en) 2008-01-16
IL190843A (en) 2013-08-29
FI1942868T4 (fi) 2023-10-12
SI3225233T1 (sl) 2019-10-30
BRPI0618133A2 (pt) 2011-08-16
DK1942868T5 (da) 2024-01-08
AR056748A1 (es) 2007-10-24
AU2006308921C1 (en) 2013-01-24
SI1942868T2 (sl) 2023-12-29
EP3593790A1 (en) 2020-01-15
NO20082180L (no) 2008-07-04
EP3225233B1 (en) 2019-08-14
WO2007053533A8 (en) 2008-07-24
HUS2000003I1 (hu) 2020-02-28
HK1245090B (en) 2020-04-09
JP5555425B2 (ja) 2014-07-23
GT200800037A (es) 2008-10-01
AU2006308921A1 (en) 2007-05-10
NO347263B1 (no) 2023-08-14
ECSP088485A (es) 2008-06-30
KR20110128957A (ko) 2011-11-30
FR20C1005I1 (fr) 2020-03-20
PL1942868T5 (pl) 2023-12-27
LUC00035I1 (es) 2017-09-28
PT1942868T (pt) 2017-06-16
HUE045421T2 (hu) 2019-12-30
KR20080065689A (ko) 2008-07-14
CN101351190A (zh) 2009-01-21
RU2432157C2 (ru) 2011-10-27
AR112443A2 (es) 2019-10-30
LUC00035I2 (es) 2017-12-01
PE20110803A1 (es) 2011-11-07
MY184364A (en) 2021-04-01
US20170021022A1 (en) 2017-01-26
EP1942868A2 (en) 2008-07-16
NZ567685A (en) 2011-07-29
US20200138952A1 (en) 2020-05-07
IL190843A0 (en) 2008-11-03
EP3225233A1 (en) 2017-10-04
JP2009513705A (ja) 2009-04-02
HUS1700035I1 (hu) 2017-11-28
EP1942868B2 (en) 2023-10-04
UA97234C2 (ru) 2012-01-25
RU2008119514A (ru) 2009-12-10
TWI480063B (zh) 2015-04-11
PE20151284A1 (es) 2015-10-05
DK1942868T3 (en) 2017-06-26
ES2627684T3 (es) 2017-07-31
CA2626531A1 (en) 2007-05-10
DK3225233T3 (da) 2019-10-14
AU2006308921B2 (en) 2012-07-19
PE20070714A1 (es) 2007-07-20

Similar Documents

Publication Publication Date Title
CR9958A (es) Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco
ECSP034613A (es) Preparacion liofilizada de pantoprazol e inyeccion de pantoprazol
AR083034A1 (es) ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO
AR088381A1 (es) Formulaciones de etanercept estabilizadas con meglumina
EA200301250A1 (ru) Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры
ECSP088962A (es) Nuevos herbicidas
CO6440528A2 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico.
TR200401793T4 (tr) Perindopril tuzu ve bunu içeren farmasötik bileşimler.
EA200901365A1 (ru) Стабилизированная фармацевтическая композиция, содержащая прегабалин
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
UA93673C2 (ru) Фармацевтическая композиция, которая содержит омега-карбоксиарилзамещенную дифенилмочевину, для лечения paka
EA200970274A1 (ru) Способы введения гипогликемических средств с длительным действием
MA31706B1 (fr) Formulations galéniques de composés organiques
BRPI0707488B8 (pt) método para a produção de uma composição de epoprostenol, composição farmacêutica e solução estável
WO2009015382A3 (en) Novel peptides that enhance tight junction permeability
EA200400819A1 (ru) Парентеральная композиция парацетамола
DE602005010488D1 (de) Diebstahlsicherungsanhänger
EA200601759A1 (ru) Композиции рамиприла
FR2959880A1 (fr) Cavite laser a extraction centrale par polarisation pour couplage coherent de faisceaux intracavite intenses
EA200100098A1 (ru) Соли пароксетина
MXPA05008572A (es) Uso de dipiridamol en combinacion con acido acetilsalicilico y un antagonista de angiotensina ii para la prevencion de accidente cerebrovascular.
DK1200088T3 (da) Sammensætning indeholdende paracetamol og drotaverin
ES2418459R1 (es) Relacionando agregacion proteica con supervivencia de levadura
NO20065898L (no) 1-heterocyklyl-1,5-dihydro-pyrido[3,2-b]indol-2-oner
AR031010A1 (es) Una composicion farmaceutica, util para inhibir el dano celular

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)